Meribank Biotech Co., Ltd (TPEX:4724)
Taiwan
· Delayed Price · Currency is TWD 14.00
+0.05 (0.36%)
Apr 29, 2026, 1:43 PM CST
Meribank Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -81.47 | -94.71 | -125.35 | -102.13 | -99.19 | Upgrade
|
| Depreciation & Amortization | 154.95 | 83.22 | 34.28 | 32.16 | 29.47 | Upgrade
|
| Other Amortization | 0.46 | 0.81 | 2.25 | - | - | Upgrade
|
| Loss (Gain) From Sale of Assets | - | -0.01 | -0.07 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 2.1 | - | 5.67 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 14.54 | -2.72 | - | -5.79 | -0.18 | Upgrade
|
| Loss (Gain) on Equity Investments | 3.63 | 11.93 | 5.41 | 5.42 | 4.51 | Upgrade
|
| Stock-Based Compensation | 7.89 | 2.51 | 1.17 | 0.02 | 0.34 | Upgrade
|
| Provision & Write-off of Bad Debts | 5.46 | 1.23 | 3.84 | -0.59 | 5.28 | Upgrade
|
| Other Operating Activities | -8.01 | -7.28 | -4.14 | -1.45 | -0.37 | Upgrade
|
| Change in Accounts Receivable | -33.03 | -29.99 | 17.6 | -6.25 | -14.2 | Upgrade
|
| Change in Inventory | 4.82 | -4.34 | 1.54 | -4.84 | -0.67 | Upgrade
|
| Change in Accounts Payable | -6.16 | 1.85 | 3.29 | 2.3 | -0.24 | Upgrade
|
| Change in Unearned Revenue | 9.59 | 22.83 | 12.22 | 10.52 | 33.6 | Upgrade
|
| Change in Other Net Operating Assets | 14.67 | -23.42 | 12.58 | 29.31 | 18.66 | Upgrade
|
| Operating Cash Flow | 89.45 | -38.09 | -29.7 | -41.33 | -23 | Upgrade
|
| Capital Expenditures | -3.84 | -248.61 | -5.8 | -4.15 | -7.21 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 0.01 | - | - | - | Upgrade
|
| Cash Acquisitions | - | 15.44 | -4.42 | -1.27 | - | Upgrade
|
| Sale (Purchase) of Intangibles | -1.05 | -95.58 | -0.88 | -0.09 | -0.31 | Upgrade
|
| Sale (Purchase) of Real Estate | -11 | - | - | - | - | Upgrade
|
| Investment in Securities | -131.9 | -14.49 | 83.62 | -23.03 | -75.83 | Upgrade
|
| Other Investing Activities | -22.3 | -19.23 | -24.37 | -16.46 | -34.72 | Upgrade
|
| Investing Cash Flow | -170.08 | -362.46 | 48.15 | -45.01 | -118.07 | Upgrade
|
| Long-Term Debt Issued | - | 175 | - | - | - | Upgrade
|
| Long-Term Debt Repaid | -77.95 | -38.76 | -22.78 | -20.34 | -17.98 | Upgrade
|
| Net Debt Issued (Repaid) | -77.95 | 136.24 | -22.78 | -20.34 | -17.98 | Upgrade
|
| Issuance of Common Stock | 120 | - | 311.6 | - | 300 | Upgrade
|
| Other Financing Activities | -28.34 | 29.94 | 7.03 | -0.32 | -0.2 | Upgrade
|
| Financing Cash Flow | 13.71 | 166.17 | 295.85 | -20.66 | 281.82 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.73 | - | - | - | - | Upgrade
|
| Net Cash Flow | -67.65 | -234.37 | 314.3 | -106.99 | 140.76 | Upgrade
|
| Free Cash Flow | 85.62 | -286.7 | -35.5 | -45.48 | -30.2 | Upgrade
|
| Free Cash Flow Margin | 18.15% | -78.24% | -15.15% | -25.25% | -18.52% | Upgrade
|
| Free Cash Flow Per Share | 0.94 | -3.60 | -0.56 | -0.72 | -0.50 | Upgrade
|
| Cash Interest Paid | 23.11 | 10.7 | 0.85 | 0.99 | 1.13 | Upgrade
|
| Cash Income Tax Paid | 0.07 | 0.03 | - | - | - | Upgrade
|
| Levered Free Cash Flow | 57.12 | -330.4 | -11.46 | -43.73 | -55.04 | Upgrade
|
| Unlevered Free Cash Flow | 71.57 | -323.71 | -10.93 | -43.12 | -54.33 | Upgrade
|
| Change in Working Capital | -10.1 | -33.06 | 47.23 | 31.04 | 37.15 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.